RLMD: Relmada Therapeutics, Inc. Total Debt to Capital

Relmada Therapeutics (RLMD) relies on outsourcing the production of drug substances to external partners, minimizing dependence on specific suppliers. The brand maintains high authority in the treatment of major depressive disorders due to the potential of REL-1017. This price chart on GURU.Markets shows that the total debt-to-equity ratio is 0.00. Supply security and strict adherence to temperature controls during transport guarantee the efficacy of these neuropsychiatric agents.

When assessing the asset quality of Relmada Therapeutics (RLMD), an investor must determine the balance between debt and equity to understand the issuer's financial autonomy. An analysis of the total debt-to-equity ratio on GURU.Markets reveals the business's degree of dependence on creditors, which is critical for a developer of unique antidepressants whose premium pricing power strategy requires minimal debt burdens to maintain stability.